Amarin Corp Plc (AMRN)

[lettruthringout]

Bhatt indirectly to Nissen: Get over it

Bhatt emphasized that the mineral oil issue alone cannot explain icosapent ethyl's benefits.

"The issue of placebo choice and potential changes in biomarkers has been thoroughly reviewed by the FDA, Health Canada, and the European Medicines Agency, all of whom have granted a broad approval for icosapent ethyl that largely mirrors the REDUCE-IT inclusion criteria," he said.

"Furthermore, for anyone who cannot get over the issue of placebo choice, icosapent ethyl has also been studied in two other randomized trials which did not use any placebo that still show its benefits – JELIS with a significant 19% reduction in clinical endpoints and CHERRY with a significant benefit on intravascular ultrasound endpoints," he added.

https://www.medpagetoday.com/meetingcoverage/esc/94270?fr=operanews

https://www.ajmc.com/view/reduce-it-vs-strength-still-missing-pieces-in-the-omega-3-puzzle